[Use of thymodepressin for treating autoimmune cytopenia]
Vinogradova IuE, Zamulaeva IA, Pavlov VV, Selivanova EI, Deĭgin VI, Smirnova SG, Orlova NV, Saenko AS · 2002 · Terapevticheskii arkhiv
Study data at a glance
- Participants or experimental model
- 22 patients with autoimmune cytopenias
- Reported results
- The report describes higher hemoglobin in autoimmune hemolytic anemia and higher platelet counts in immune thrombocytopenia, alongside reductions in lymphocyte activation measures.
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- Uncontrolled clinical report; changes cannot establish an independent treatment effect.
- The abstract supplies no reliable comparative effect size or comprehensive safety estimate.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Source access and review scope
Original publication abstract checked; full methodological appraisal pending.
Recorded source-check date: 2026-11-05. This date does not imply a completed systematic review.
Citation and original source
Original source: Vinogradova IuE, Zamulaeva IA, Pavlov VV, Selivanova EI, Deĭgin VI, Smirnova SG, Orlova NV, Saenko AS. [Use of thymodepressin for treating autoimmune cytopenia] Terapevticheskii arkhiv 2002.
Molekul research summary: https://molekul.io/research/auto-12360601. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry